It is postulated that this may be due to the fact that aromatase inhibitors effectively reduce the amount of active oestrogen rendering the ER monomeric and inactive, whilst the agonist activity of Tamoxifen can still be activated by MEKK1 <a href=http://stromectol.autos/>ivermec</a> Continued clinical studies have resulted in further information which better indicates the incidence of adverse reactions with Tamifine tamoxifen citrate as compared to placebo
